/SONN
SONN Stock - Sonnet BioTherapeutics Holdings, Inc.
Healthcare|BiotechnologyNASDAQ
$1.26-59.35%
$1.84 (-59.35%) • Dec 2
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.61
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.39
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SONN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.25 – $1.27
TARGET (TP)$1.45
STOP LOSS$1.16
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.47
52W High$19.30
52W Low$1.08
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.00M | $18,626 | $147,805 | $349,943 | $483,626 |
| Gross Profit | N/A | $18,626 | $147,805 | $-21,094,076 | $483,626 |
| Gross Margin | 0.0% | 100.0% | 100.0% | -6027.9% | 100.0% |
| Operating Income | $-15,844,115 | $-11,849,471 | $-18,792,617 | $-29,669,359 | $-25,087,436 |
| Net Income | $-16,112,737 | $-7,437,232 | $-18,832,694 | $-29,774,323 | $-25,005,987 |
| Net Margin | -1611.3% | -39929.3% | -12741.6% | -8508.3% | -5170.5% |
| EPS | $-3.95 | $-11.35 | $-145.12 | $-1203.05 | $-2507.83 |
Company Overview
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
SONNBeat Rate
44%
Last 16 quarters
Avg Surprise
-3308.8%
EPS vs Estimate
Beats / Misses
7/9
Last 12 quarters
Latest EPS
$-0.95
Q3 2025
EPS Surprise History
Q4 23
+48.9%
$-2.09vs$-4.09
Q1 24
-175.6%
$-2.48vs$-0.90
Q2 24
+300.0%
$0.56vs$0.14
Q3 24
-636.8%
$-5.60vs$-0.76
Q4 24
+24.0%
$-3.83vs$-5.04
Q1 25
-12.2%
$-1.56vs$-1.39
Q2 25
+3.3%
$-0.89vs$-0.92
Q3 25
-93.9%
$-0.95vs$-0.49
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | — | — | — | — |
Q4 2025 | Dec 16, 2025 | — | — | — | — |
Q3 2025 | Aug 13, 2025 | $-0.49 | $-0.95 | -93.9% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.92 | $-0.89 | +3.3% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $-1.39 | $-1.56 | -12.2% | ✗ MISS |
Q4 2024 | Dec 19, 2024 | $-5.04 | $-3.83 | +24.0% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.76 | $-5.60 | -636.8% | ✗ MISS |
Q2 2024 | May 14, 2024 | $0.14 | $0.56 | +300.0% | ✓ BEAT |
Q1 2024 | Feb 14, 2024 | $-0.90 | $-2.48 | -175.6% | ✗ MISS |
Q4 2023 | Dec 18, 2023 | $-4.09 | $-2.09 | +48.9% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.31 | $-22.86 | -7274.2% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.49 | $-59.78 | -12100.0% | ✗ MISS |
Q1 2023 | Feb 13, 2023 | $-1.10 | $-140.66 | -12687.3% | ✗ MISS |
Q4 2022 | Dec 15, 2022 | $-1.51 | $-1.67 | -10.6% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-1.96 | $-1.82 | +7.1% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-1.68 | $-344.75 | -20420.8% | ✗ MISS |
Q1 2022 | Feb 8, 2022 | $-738.76 | $-246.25 | +66.7% | ✓ BEAT |
Q4 2021 | Dec 17, 2021 | $-3.08 | $-2.45 | +20.5% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | — | $-664.88 | — | — |
Latest News
Hyperliquid Strategies And Sonnet BioTherapeutics Complete Business Combination; New Company To Trade on Nasdaq As "PURR" While Sonnet Becomes A Wholly Owned Subsidiary
📈 PositiveBenzinga•Dec 2, 2025, 09:31 PM
Sonnet BioTherapeutics Holdings shares are trading lower after the company announced its stockholders approved a business combination with Hyperliquid Strategies and Rorschach I.
➖ NeutralBenzinga•Dec 2, 2025, 07:00 PM
Sonnet BioTherapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -29.68%
📉 NegativeBenzinga•Dec 2, 2025, 02:49 PM
Sonnet BioTherapeutics Stockholders Approve Business Combination With Hyperliquid Strategies And Rorschach I
📈 PositiveBenzinga•Dec 2, 2025, 02:23 PM
Sonnet BioTherapeutics Collaborates With Spanios On Non-Clinical Study Using NAM-Based PDT Platforms That Emulate TME Ex Vivo To Evaluate Effect Of SON-1010 In Soft Tissue Sarcoma
➖ NeutralBenzinga•Oct 15, 2025, 02:05 PM
Sonnet BioTherapeutics jumps over 320%, combines business for HYPE crypto reserve
📈 PositiveSeeking Alpha•Jul 14, 2025, 10:50 AM
Frequently Asked Questions about SONN
What is SONN's current stock price?
Sonnet BioTherapeutics Holdings, Inc. (SONN) is currently trading at $1.26 per share. The stock has moved -59.35% today.
What is the analyst price target for SONN?
No analyst price targets are currently available for this stock.
What sector is Sonnet BioTherapeutics Holdings, Inc. in?
Sonnet BioTherapeutics Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SONN's market cap?
Sonnet BioTherapeutics Holdings, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does SONN pay dividends?
No, Sonnet BioTherapeutics Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBOLD
Boundless Bio, Inc.
$1.22
Mkt Cap: $0.0B
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$7.11
Mkt Cap: $0.0B
IBIO
iBio, Inc.
$1.98
Mkt Cap: $0.0B
INTS
Intensity Therapeutics, Inc.
$0.41
Mkt Cap: $0.0B
ITRM
Iterum Therapeutics plc
$0.37
Mkt Cap: $0.0B
KLTO
Klotho Neurosciences, Inc.
$0.39
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
RLYB
Rallybio Corporation
$0.79
Mkt Cap: $0.0B
TAOX
TAO Synergies Inc.
$5.03
Mkt Cap: $0.0B
XCUR
Exicure, Inc.
$5.92
Mkt Cap: $0.0B
Explore stocks similar to SONN for comparison